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The subcutaneous implantable cardioverter-defibrillator
(S-ICD) is a safe and effective treatment for prevention of
sudden cardiac death.1 It is typically not used in patients
who require additional therapies conferred by transvenous
implantable cardioverter-defibrillator (TV-ICD) systems,
such as bradycardia pacing or antitachycardia pacing (ATP)
for ventricular tachycardia (VT). Despite reports of success-
ful S-ICD implantation in patients with other cardiac implant-
able electronic devices (CIEDs),2–5 we are not aware of any
reports to date in which S-ICD implantation complemented a
pre-existing TV-ICD as a backup device for successful defi-
brillation. We report the case of a patient who presented with
this clinical dilemma.Case report
An 83-year-old man with a history of ischemic cardiomyop-
athy and dual-chamber TV-ICD placement 11 years prior for
secondary prevention of VT was referred to the electrophys-
iology service at Bellin Health Heart & Vascular Center
(Green Bay, WI), as his device generator had reached end
of life. Because the device was originally implanted for sec-
ondary prevention, it was felt that defibrillator threshold
(DFT) testing was warranted. Furthermore, the patient had
experienced a decline in his left ventricular ejection fraction
(LVEF) to 35% from 50% 1 year earlier.
During DFT testing with the new generator (INOGEN
ICD; Boston Scientific Corp. (i.e. should read ‘Corp.,’), St.
Paul, MN), ventricular fibrillation (VF) was induced, and
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external defibrillation. None of the standard approaches was
successful in adequately reducing the DFT below the device’s
maximal energy, including reversal of polarity, “cold can”
configuration, and even posterolateral placement of a subcu-
taneous array in the left chest. After it was felt that all reason-
able available options were exhausted and additional VF
inductions would not be beneficial, the newly implanted
generator was left in place, and the pocket was closed. The pa-
tient was allowed approximately 24 hours of recovery time,
after whichDFT testingwas repeated, with the same outcome.
Alternative options were discussed with the patient,
including maintaining the status quo (which we felt was
not an acceptable option at that point), pursuing a surgical
approach for epicardial patch placement, or implantation of
an S-ICD, and he opted for the latter modality. However,
because historically he had responded to ATP therapy for
VT and required atrial pacing nearly 100% of the time, we
planned to preserve his TV-ICD.
Preliminary screening for S-ICD implantation showed he
was a suitable candidate with respect to his QRS complexes,
both paced and intrinsic. We proceeded with implantation of
the S-ICD via the standard approach (Figure 1). VF was
induced by a 50 Hz electrical burst delivered from the
S-ICD, appropriately detected, and converted with a 65 J stan-
dard polarity shock (Figure 2A). Shock impedance was 72
ohms, and the time to therapy was 13 seconds. The device
was programmed with the primary sensing vector
(Figure 2B) at 2! gain and shock zone threshold of 230 beats
per minute (bpm). DFT testing of the S-ICDwas repeated with
3 different configurations of the TV-ICD at maximal pacing
output: atrial sensing–ventricular pacing, atrial pacing–ven-
tricular pacing, and atrial pacing–ventricular fusion. In each
case the S-ICD succeeded in restoring sinus rhythm, with no
inappropriate sensing resulting in inappropriate therapies.
Following our unsuccessful attempts to achieve a safe




 Despite emerging evidence demonstrating
comparable implantable cardioverter-defibrillator
(ICD) efficacy with or without routine defibrillator
threshold (DFT) testing, in subsets of patients who
are felt to be at particularly high risk and for whom
guideline recommendations are less clear, DFT
testing may be pursued by an implanting physician.
 In cases where DFT testing is felt to be clinically
indicated, one should keep in mind that successful
defibrillation of ventricular fibrillation is a
probabilistic phenomenon, and performance in the
past may not predict performance in the future.
 In this setting, subcutaneous ICD (S-ICD) therapy
may be considered as a backup to a transvenous ICD
in cases where a patient requires transvenous
therapies, but the usual system revisions have been
unsuccessful in achieving a satisfactory DFT.
Rigorous testing of both devices should be
performed to minimize interactions, particularly
S-ICD double counting and undersensing.
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transvenous device to treat VT with shocks. Furthermore,
TV-ICD defibrillation therapies for VF were left on in the
event they may be successful and with the acknowledgment
that the S-ICD would serve as a backup if the TV-ICD failed
to restore sinus rhythm. The VT/VF detection times of the
TV-ICD were set short to preferentially try defibrillation first
by the TV-ICD. The TV-ICD was programmed in DDD
mode with a long atrioventricular interval to both helpFigure 1 Anterior-posterior (A) and lateral (B) view chest radiographs follpromote intrinsic conduction with narrow QRS complexes
and minimize inappropriate sensing resulting in inappropriate
therapies. The patient tolerated the procedure well, and no
complications were encountered during the implantation.
Just prior to reaching 6 months post-implantation, the pa-
tient experienced a run of symptomatic VT, which was appro-
priately converted with a 41 J shock from his TV-ICD
(Figure 2C). Two days later he had 5 more runs of VT, all
of which were terminated in like fashion. Interrogation of
both ICD devices demonstrated normal function without any
evidence of adverse interaction between them. The patient
was started on sotalol and had no further recurrence of VT.Discussion
S-ICD devices have been shown to be a safe and effective
alternative to traditional TV-ICD devices in appropriate candi-
dates.4 Previous reports have documented successful implan-
tation of S-ICD devices in the presence of other CIEDs,
including transvenous pacemakers,4,5 epicardial patches,2 car-
diac contractility modulators, and vagal nerve stimulators.3 In
all cases the S-ICD was shown to function properly after un-
dergoing rigorous testing for device–device interactions, espe-
cially defects in its sensing and shock delivery capabilities.
Noting the historical significance of pacemaker–defibrillator
interactions, we had concerns regarding whether the 2 devices
would interfere with one another, in terms of both can–can in-
teractions and the ability of the S-ICD algorithm to appropri-
ately sense ventricular arrhythmias while the TV-ICD was
pacing. Limited reports of experiences with concomitant pace-
maker and S-ICD implantation have been uneventful when
testing sensing and shocking capabilities of the S-ICD with
a variety of pacemaker settings.2,3
In our case, we found the S-ICD was able to appropriately
sense ventricular arrhythmias with the primary sensing vector
(i.e., from the xiphoid electrode to the S-ICD generator) at
2! gain. There was occasional double counting noted withowing subcutaneous implantable cardioverter-defibrillator implantation.
Figure 2 A: Subcutaneous implantable cardioverter-defibrillator (S-ICD) appropriately detecting and converting ventricular fibrillation on induction testing.B:
S-ICD programmed with primary sensing vector and 2! gain demonstrating good capture and occasional double counting. C, Transvenous ICD delivering
maximal shock (36.5 J) in response to spontaneous ventricular tachycardia.
308 Heart Rhythm Case Reports, Vol 3, No 6, June 2017ventricular pacing (Figure 2B), so sensing vector selection
was in part determined by which vector was least affected
by this phenomenon. As a precaution, we set the S-ICD
shock zone threshold at 230 bpm to ensure that even in con-
ditions of double counting the threshold would exceed themaximum TV-ICD sensor and tracking rates of 110 bpm
and minimize inappropriate shocks. Implantation of an S-
ICD in the setting of other CIEDs in prior reports was amatter
of pragmatism where it was felt a TV-ICD was not specif-
ically indicated or was contraindicated for prevention of
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tient already had a functioning TV-ICD in place, but despite
manipulation of the shock vector with various configurations
and the addition of a subcutaneous electrode array, a safe
DFT could not be achieved during the generator change pro-
cedure. During implantation of the TV-ICD 11 years prior,
DFT testing had been successful, with no more than a 17 J
shock. This was also the case during a generator change 5
years prior to presentation.
The role of DFT testing during ICD implantation remains
controversial, with well-intentioned arguments from both pro-
ponents and opponents of the practice. Using a conventional
10 J safety margin, high DFTs requiring system modification
occur in approximately 2%–12% of implants.6 A number of
factors have been implicated as being associated with higher
DFTs, such as low LVEF, New York Heart Association func-
tional class III/IV heart failure, nonischemic cardiomyopathy,
male sex, increased age, secondary prevention indication, and
others.6,7 Proposed benefits of DFT testing and subsequent
system modification for high DFTs include identification of
catastrophic, albeit rare, device failure; potential
improvement in first shock success; and detection of
abnormal lead function. Historically, DFT testing has been a
mainstay of clinical trials demonstrating the mortality benefit
of ICD therapy and was incorporated into major trials for
both primary and secondary prevention, as well as device
labeling.8,9 Because system modifications can ameliorate
high DFTs, some would argue the implanter has an ethical
obligation to ensure, to the best of his or her ability, that the
ICD system functions appropriately.
On the other hand, there are limitations and risks associated
with DFT testing. Owing to the probabilistic nature of defibril-
lation, there is no guarantee that successful DFT testingwill pre-
dict future successful termination of VT/VF. Achieving a safe
DFT at the time of implantation does not account for substrate
changes, metabolic derangements, medication effects, and other
factors that may subsequently affect shock efficacy. DFT testing
itself is not devoid of risk to the patient, nor are system revisions
aimed at achieving an acceptable DFT. Improvements in device
characteristics have led some to avoid the routine practice of
DFT testing at initial implantation in up to 30% of cases.7,10
This perspective has been reinforced by the publication of
randomized controlled trial data from the Shockless IMPLant
Evaluation (SIMPLE) and the NO Regular Defibrillation
testing In Cardioverter Defibrillator Implantation (NORDIC
ICD) trials.11,12 Both showed no significant difference in
shock efficacy in adult patients undergoing ICD implantation,
randomized to either receive or forgo DFT testing. They
additionally supported the overall safety of DFT testing.
Guidelines from the 2015 HRS/EHRA/APHRS/SOLAECE
expert consensus document confer a class IIa (Level of
Evidence, B-R) recommendation in this regard: “It is
reasonable to omit defibrillation efficacy testing in patients
undergoing initial left pectoral transvenous ICD
implantation procedures where appropriate sensing, pacing,
and impedance values are obtained with fluoroscopically
well-positioned RV leads.”13Despite increasing evidence demonstrating inconsequen-
tial DFT testing in a majority of patients receiving high-
output devices, our ability to accurately identify patients in
whom system revision may be beneficial remains limited.
In the case of our patient, his constellation of risk factors
and newly depressed LVEF compelled us to pursue DFT
testing. Unfortunately, the standard revision techniques
were unable to yield a satisfactory DFT, and we ultimately
pursued an alternative plan of S-ICD implantation as a
backup to his transvenous device. We suspect its success
was related both to a different shock vector achieved by the
subcutaneous system (Figure 1) and to a higher energy deliv-
ered as compared with the existing TV-ICD. S-ICD implan-
tation may therefore be considered as an option in rare
situations when a pre-existing TV-ICD is incapable of
achieving a satisfactory DFT and available alternative op-
tions have been exhausted.Acknowledgments
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